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Background: Adolescent females with ovarian failure require estrogen therapy for induction of puberty and other
important physiologic effects. Currently, health care providers have varying practices without evidence-based
standards, thus investigating potential differences between oral and transdermal preparations is essential. The
purpose of this study was to compare the differential effects of treatment with oral conjugated equine estrogen
(OCEE), oral 17β estradiol (OBE), or transdermal 17β estradiol (TBE) on biochemical profiles and feminization in girls
with ovarian failure.
Study design: 20 prepubertal adolescent females with ovarian failure, ages 12–18 years, were randomized to OCEE
(n = 8), OBE (n = 7), or TBE (n = 5) for 24 months. Estrogen replacement was initiated at a low dose (0.15 mg OCEE,
0.25 mg OBE, or 0.0125 mg TBE) and doubled every 6 months to a maximum dose of 0.625 mg/d OCEE, 1 mg/d
OBE, or 0.05 mg/d TBE. At 18 months, micronized progesterone was added to induce menstrual cycles. Biochemical
markers including sex hormones, inflammatory markers, liver enzymes, coagulation factors, and lipids were obtained
at baseline and 6 month intervals. Differences in levels of treatment parameters between the groups were
evaluated with one-way analysis of variance (ANOVA). The effect of progesterone on biochemical markers was
evaluated with the paired t-test.
Results: Mean (±SE) estradiol levels at maximum estrogen dose (18 months) were higher in the TBE group
(53 ± 19 pg/mL) compared to OCEE (14 ± 5 pg/mL) and OBE (12 ± 5 pg/mL) (p≤ 0.01). The TBE and OBE groups
had more effective feminization (100% Tanner 3 breast stage at 18 months). There were no statistical differences in
other biochemical markers between treatment groups at 18 months or after the introduction of progesterone.
Conclusions: Treatment with transdermal 17β estradiol resulted in higher estradiol levels and more effective
feminization compared to oral conjugated equine estrogen but did not result in an otherwise different biochemical
profile in this limited number of heterogeneous patients. OBE and TBE provide safe and effective alternatives to
OCEE to induce puberty in girls, but larger prospective randomized trials are required.
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The use of estrogen in girls with ovarian failure is necessary
to induce puberty, cause feminization and deliver other
important physiologic effects. It is apparent that pediatric
endocrinologists have widely varying practices regarding
the type and dose of estrogen used for the feminization of
hypogonadal girls [1,2]. Ultimately, since adolescents with
ovarian failure will need estrogen therapy for a prolonged
period of time, investigating potential differences between
oral and transdermal preparations is important and neces-
sary. Several studies have compared estrogen preparations
in adult females, but the adolescent population is relatively
understudied. A recent study in girls with TS demonstrated
more physiologic estrogen concentrations with the use of
the transdermal estrogen preparation [1].
Classically, estrogen has been thought to have cardio-
protective effects. In hypogonadal young adult women
increasing doses of oral estrogen are associated with de-
creasing intima media thickness, increasing high-density
lipoprotein (HDL) levels, and decreasing plasma glucose
levels [3]. These effects need to be weighed against the
potentially prothrombotic effects of estrogen highlighted
by the Women’s Health Initiative (WHI) [4]. Some have
theorized that the higher frequency of adverse events in
the WHI reflects the type of estrogen used in these studies,
oral conjugated equine estrogen (OCEE). Furthermore,
other adverse effects associated with use of OCEE in adults,
such as elevation of c-reactive protein, liver enzymes, in-
creases in pro-coagulation factors, hypertension, decreases
in HDL cholesterol, and increases in triglycerides, have not
been seen with transdermal 17β estradiol (TBE) [5-11].
Use of oral 17β estradiol (OBE) in adult females has had
variable effects [12], suggesting that OCEE itself may
have inflammatory or metabolic effects independent of
the route of estrogen delivery, as it is composed of many
different forms of estrogen (primarily estrone).
The need for estrogen replacement in adolescence is
not limited to girls with TS. Lantiga et al. showed that 18%
of female childhood cancer survivors will develop ovarian
failure by age 33, necessitating long-term estrogen use [13].
Other studies have shown that the incidence of impaired
ovarian function or frank failure is up to 85% of cancer
survivors after bone marrow transplant [14]. Furthermore,
adolescent cancer survivors with ovarian failure often have
baseline liver damage due to their initial treatment regimen,
and using a less hepatotoxic form of estrogen could have
important clinical significance.
In addition to estrogen replacement therapy, proges-
terone therapy is required to induce menstrual cycles.
There is a lack of studies exploring the metabolic
effects of adding progesterone to estrogen therapy in
girls. The Heart Estrogen/Progesterone Replacement
study (HERS) and WHI studies highlighted the dele-
terious effects of progesterone in adults, as combinedtherapy resulted in higher rates of stroke and other
cardiovascular disease [15-17].
This randomized, open-label feasibility study was de-
signed to investigate the differential effects of treatment
with three common forms of estrogen on the biochem-
ical profiles in hypogonadal girls, as well as to evaluate
the discrete effects of progesterone therapy. We hypoth-
esized that transdermal estrogen would have less harm-
ful biochemical effects than oral forms of estrogen, and
that there would be differences between the biochemical
profiles of the two oral forms of estrogen, OCEE and
OBE. Additionally, we hypothesized there would be no




All adolescent females between the ages of 12–18 years
with primary or secondary ovarian failure in whom es-
trogen therapy was clinically indicated were invited to
participate in the randomized open-label study. During a
4-year period (2007–2011), 25 study participants were
assessed for eligibility, recruited from current patients
and new referrals in the Pediatric Endocrinology Clinic
at Lucile Packard Children’s Hospital at Stanford. All
eligible patients seen in the clinic were approached to
participate. Twenty patients were enrolled in the study.
We excluded girls who had Tanner 2 breast stage or
greater, spontaneous menses, or previous use of estrogen.
Written informed consent was obtained from parents
of all participants before enrollment, and a written
assent was obtained from all study participants. The
protocol and consents were approved by the Stanford
University Administrative Panel on Human Subjects in
Medical Research.
Protocol
Participants were randomized to one of 3 forms of
estrogen: OCEE (Premarin, Wyeth Pharmaceuticals,
Madison, New Jersey), OBE (Estrace, Warner Chilcott,
Dublin Ireland) or TBE (Vivelle-Dot, Novartis, East
Hanover, New Jersey). Block randomization was used,
with sequentially numbered envelopes that contained
treatment group assignments. Participants and care
providers were not blinded to the treatment groups.
Estrogen replacement was initiated at a low dose
(0.15 mg/d OCEE, 0.25 mg/d OBE, or 0.0125 mg/d TBE)
and doubled every 6 months to a maximum dose starting
at 12 months of 0.625 mg/d OCEE, 1 mg/d OBE, or
0.05 mg/d TBE. These doses were selected based on
published equivalencies at the start of the study [18].
At 18 months, micronized progesterone (Prometrium,
Abbott, Abbott Park, Illinois) at a dose of 200 milligrams
daily was introduced on days 17–26 of each month, and
Figure 1 Enrollment, randomization, and follow-up of the study participants.
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terone on days 27–31 of each month to induce a
menstrual cycle. Study participants were followed for
6 months after the introduction of progesterone, for a
total study time of 24 months.
Evaluation and laboratory testing
History and physical exams, including assessment of
feminization by Tanner staging and breast diameter were
obtained at baseline and every 6 months for 24 months.
The biochemical profile was obtained as a morning fast-
ing venous sample at baseline and 6 month intervals that
coincided with the subject’s clinic visits. There was not a
specific attempt to avoid sampling during illnesses or
during menses. Each sample included biochemical
markers of inflammation (high-sensitivity c-reactive protein
[hs-CRP] and fibrinogen), sex hormones (estradiol,
estrone, estrone sulfate, luteinizing hormone [LH],
follicle-stimulating hormone [FSH]), liver enzymes and
binding proteins (alanine aminotransferase [ALT], aspartate
aminotransferase [AST], sex hormone binding globulin),
lipid metabolism (cholesterol, HDL, low-density lipoprotein
[LDL], triglycerides), coagulation (antithrombin activity),
insulin resistance (insulin, fasting glucose), growth
(insulin-like growth factor −1 [IGF-1] and insulin-like
growth factor binding protein-3 [IGFBP-3]), and bloodpressure (plasma renin activity). All assays were per-
formed at Esoterix (Calabasas Hills, California). The
hs-CRP assay was performed by nephelometry. The es-
tradiol assay was performed by liquid chromatography/
tandem mass spectrometry (LC-MS/MS) with a lower level
of detection of 1 pg/mL.
Statistics
Differences in levels of treatment parameters between
the three groups were evaluated with one-way analysis of
variance (ANOVA). Results are displayed as mean ± SE
unless otherwise noted. The comparison within groups be-
tween baseline and 18 months was evaluated with a t-test,
and the effect of progesterone on biochemical markers
was evaluated with paired t-test. All statistical analysis
was performed using SAS Enterprise Guide version 4.3
(SAS Institute, Cary, North Carolina). Subjects with hs-
CRP level greater than 10 mg/L were excluded from
analysis of the inflammatory marker at that study time
point as hs-CRP levels above this cutoff generally sug-
gest an acute systemic inflammatory condition and thus
cannot be used to predict cardiovascular risk [19]. One
subject with diabetes mellitus was excluded from ana-
lysis of glucose and insulin levels. One subject was ex-
cluded from all height analysis due to inability to obtain
accurate standing heights. Subject data were excluded
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if non-adherence to therapy was reported.
Results
Twenty adolescent females were enrolled during the
study time period (OCEE n = 8; OBE n = 7; TBE n = 5)
(Figure 1, Table 1). There were no significant differences
in baseline age, height, and weight when comparing the
3 treatment groups. Twelve out of 20 participants had TS
(OCEE n = 4; OBE n = 5; TBE n = 3), while the remain-
der had primary or secondary ovarian failure from pi-
tuitary disease or chemotherapy. As can be observed in
Table 1, the groups included both hypergonadotropic
and hypogonadotropic subjects. At study onset 12 subjects
(11 subjects with TS) were treated with recombinant
growth hormone (rGH).
Biochemical and growth data collected at baseline are
shown by treatment group in Table 2. Mean estradiol levels
were in the prepubertal range (overall mean 3 ± 1 pg/mL).
There were no significant differences in baseline bio-
chemical markers between the 3 groups, except for
serum glucose concentration, which was not consid-
ered clinically significant. Biochemical and growth data
after 18 months of estrogen-only therapy are shown inTable 1 Baseline clinical characteristics of study subjects
Group Age (y) Height SDS BMI (kg/m2)
OCEE 15 −1.065 15.3
OCEE 14.27 −3.835 13.2
OCEE 12.98 −1.211 26.2
OCEE 15.21 −1.678 40.2
OCEE 13.31 −2.922 19.0
OCEE 14.36 −1.577 19.3
OCEE 12.9 −2.997 22.2
OCEE 12.56 −1.866 20.1
Mean ± SE 13.8 ± 0.4 −2.14 ± 0.35 22 ± 3
OBE 16.11 0.061 18.5
OBE 13.62 −3.141 18.2
OBE 14.15 −1.532 20.0
OBE 16.05 −4.203 17.0
OBE 14.3 −2.723 20.5
OBE 15.32 −4.486 19.4
OBE 12.02 −1.608 19.1
Mean ± SE 14.5 ± 0.6 −2.52 ± 0.61 19 ± 0.4
TBE 15.32 0.291 16.6
TBE 13.75 −2.637 13.0
TBE 12.5 −3.03 19.1
TBE 15.43 −3.079 18.5
TBE 14.16 −3.742 19.5
Mean ± SE 14.2 ± 0.5 −2.44 ± 0.71 17.4 ± 1.2Table 3. The mean estradiol level in the TBE group at
18 months (53 ± 19 pg/mL, p ≤ 0.01) was significantly
higher compared to subjects treated with both types of
oral estrogen. Estrone and estrone sulfate levels in the
OBE group trended higher than in the other groups.
There were no statistical differences between treatment
groups at 18 months in gonadotropins, markers of inflam-
mation, lipid metabolism, growth, insulin resistance, liver
enzymes, and renin.
Trends in estradiol levels at 6 month intervals are
shown in Figure 2a. Higher estradiol levels are noted in the
TBE group compared to OBE and OCEE but with large
variability within the groups. All groups demonstrated
a trend of increasing estradiol levels throughout the
estrogen-only portion of the study. A larger percentage of
subjects in the TBE group had estradiol levels > 20 pg/mL.
Trends towards higher estrone sulfate levels were seen
in OBE subjects throughout the estrogen-only treat-
ment period (Figure 2b). Mean estrone sulfate level at
12 months was significantly higher in subjects treated
with OBE (378 ± 99 ng/dL, p < 0.01) compared to sub-
jects treated with OCEE or TBE (157 ± 49 ng/dL and
42 ± 8 ng/dL, respectively), and a similar trend was ap-
parent at 18 months as well.Diagnosis Years on GH FSH LH
Kallmann syndrome - 2 0.47
BMT - 194 86
BMT - 117 51
Turner syndrome - 55 29
Turner syndrome 3.5 58 13
Panhypopituitarism 5 0.027 0.009
Turner syndrome 1.7 65 16
Turner syndrome 2.3 197 15
3.1 ± 0.7 86 ± 27.2 26 ± 10.3
Kallmann syndrome - 0.656 0.041
AI - 144 14
Turner syndrome 9.4 46 12
Turner syndrome 0.8 117 26
Turner syndrome 3.7 40 8.5
Turner syndrome 1.7 70 16
Turner syndrome 0.7 76 13
3.3 ± 1.6 71 ± 18.3 13 ± 3
Kallmann syndrome - 1.5 0.15
Delayed puberty - 3 0.571
Turner syndrome 5 118 24
Turner syndrome 0.8 114 17
Turner syndrome 7.3 144 26
4.4 ± 1.9 76 ± 30.6 14 ± 5.6







Estradiol (pg/mL) 3.1 ± 1.1 1.2 ± 0.3 5.2 ± 3.5
Estrone (pg/mL) 11.3 ± 4.2 5.1 ± 0.8 9.3 ± 2.4
Estrone Sulfate (ng/dL) 18 ± 6.5 10 ± 1.8 11 ± 0.9
FSH (mIU/mL) 86 ± 27.2 71 ± 18.3 76 ± 30.6
LH (mIU/mL) 26 ± 10.3 13 ± 3 14 ± 5.6
SHBG (nmol/L) 63 ± 22 52 ± 11 67 ± 13.4
HS-CRP (mg/L) 1.5 ± 0.9 2.6 ± 2.1 1.5 ± 1.2
Fibrinogen Activity (mg/dL) 305 ± 29.2 280 ± 25.3 291 ± 30.6
Antithrombin Activity (%) 115 ± 4.4 125 ± 5 120 ± 4
Glucose (mg/dL) 74 ± 2.7a 85 ± 2.8 84 ± 1.7
Insulin (uIU/mL) 7.2 ± 2 5.1 ± 1.3 4.5 ± 1
AST (U/L) 39 ± 8.2 25 ± 2.2 25 ± 0.8
ALT (U/L) 46 ± 18.7 22 ± 3.6 16 ± 2.1
Cholesterol (mg/dL) 187 ± 15.3 168 ± 7.2 167 ± 11.1
Triglycerides (mg/dL) 140 ± 21.8 76 ± 13.9 101 ± 16.3
HDL (mg/dL) 49.3 ± 4 55 ± 6.2 49 ± 5.8
LDL (mg/dL) 113 ± 16.1 94 ± 5.1 97 ± 7.9
Plasma Renin (ng/dL/h) 192 ± 41.4 230 ± 71 229 ± 78.7
IGFBP-3 (mg/L) 3.1 ± 0.5 3.9 ± 0.2 4 ± 0.6
IGF-1 (ng/mL) 226 ± 50.2 361 ± 62 318 ± 84
ap < 0.05, differences in mean values between groups at baseline
Table 3 Treatment parameters at maximum estrogen








Weight (kg) 53.8 ± 10.1 43.6 ± 4 40.6 ± 3.1
Change in Weight
from baseline (kg)
5.9 ± 0.7 7.1 ± 1.6 7.2 ± 0.8
Height (cm) 153.2 ± 2.9 147.6 ± 3.9 148.6 ± 3.5
Change in Height
from baseline (cm)
6.3 ± 1.3 8.1 ± 1.3 8.2 ± 1.7
Estradiol (pg/mL) 14 ± 5a 12 ± 5 53 ± 19a,b
Estrone (pg/mL) 57.7 ± 22.6a 53.4 ± 28 26 ± 4a
Estrone Sulfate (ng/dL) 209 ± 68.1a 364.8 ± 153a 72 ± 27.9a
FSH (mIU/mL) 30 ± 9.4 88 ± 25.6 29 ± 26.4
LH (mIU/mL) 29 ± 14.5 44 ± 13.7a 4.8 ± 3.7
SHBG (nmol/L) 130 ± 38.3 35.5 ± 7.4 59 ± 20.2
HS-CRP (mg/L) 6.27 ± 4 0.5 ± 0.2 0.1 ± 0.03
Fibrinogen Activity
(mg/dL)
347 ± 59.8 284 ± 20.2 205 ± 38.9
Antithrombin Activity (%) 109 ± 3.2 121 ± 5.4 102 ± 5
Glucose (mg/dL) 82 ± 5.5 83 ± 3.8 82 ± 0
Insulin (uIU/mL) 19.6 ± 12.8 5.5 ± 1.2 3.9 ± 0.7
AST (U/L) 47 ± 13.6 24 ± 3.3 19 ± 1.2
ALT (U/L) 55 ± 26.6 23 ± 5.3 15 ± 3.5
Cholesterol (mg/dL) 177 ± 18.7 160 ± 0.6 155 ± 19.1
Triglycerides (mg/dL) 195 ± 72.4 126 ± 42.3 62 ± 5.5
HDL (mg/dL) 54 ± 5.1 49 ± 6 54 ± 10.7
LDL (mg/dL) 95 ± 11.2 91 ± 5.8 85 ± 11.3
Plasma Renin (ng/dL/h) 313 ± 83 178 ± 46 243 ± 103.5
IGFBP-3 (mg/L) 2.9 ± 0.4 3.6 ± 0.4 3.2 ± 0.1
IGF-1 (ng/mL) 266 ± 73.1 482 ± 73.6 355 ± 71
ap < 0.05, differences in mean values within groups, baseline vs 18 months.
bp < 0.05, differences in mean values between groups at 18 months.
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Tanner 3 breast stage at each 6 month interval is
shown in Figure 3. All subjects in the TBE and OBE
group were feminized by 18 months, whereas only 75%
(6/8) of subjects in the OCEE group achieved Tanner 3
breast stage before or 6 months after the scheduled
introduction of progesterone.
To evaluate the effect of progesterone therapy, biochem-
ical markers were reassessed after 6 months of estrogen
plus progesterone therapy. Participants from the three es-
trogen groups whose data were available for both month
18 and month 24 were pooled for analysis (Table 4). Al-
though downward trends in estradiol levels and upward
trends in fibrinogen and hs-CRP were observed, there was
no statistically significance difference between levels of the
biochemical markers before versus after the introduction
of progesterone. An increase in weight after the introduc-
tion of progesterone was observed. After 6 months of pro-
gesterone therapy, 5 out of 10 subjects with an intact
uterus achieved menarche. Pelvic ultrasounds obtained on
3 out of the 5 subjects who did not have menarche at the
end of the study period demonstrated a prepubertal-sized
uterus, and an endometrial stripe was only detected in 1/3
of those girls.Discussion
Estrogen replacement therapy is essential for girls with
ovarian failure to induce puberty and deliver other
estrogen-dependent effects. Currently, there is no con-
sensus on the optimal route of estrogen delivery or dose.
This 24 month prospective, randomized trial demon-
strates that treatment with either transdermal or oral
17β estradiol resulted in higher estradiol levels and more
effective feminization compared to oral conjugated es-
trogens at the doses selected but did not result in an
otherwise different biochemical profile.
Our results are consistent with other studies of hypo-
gonadal girls which have shown similar biochemical pro-
files between oral and transdermal estrogen treatment,
but those studies were conducted over a shorter dur-
ation and limited to girls with TS. In a study comparing
ba
Figure 2 Estradiol (panel a) and estrone sulfate (panel b) from baseline through 24 months of estrogen-alone therapy in patients
treated with oral conjugated estrogen (OCEE), oral 17β estradiol (OBE) or transdermal 17β estradiol (TBE). (*) TBE, OBE subject with
reported non-adherence.
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with TS treated with growth hormone, investigators
concluded that there was no difference in plasma lipids,
insulin, or fibrinogen levels with treatment using either
form of estrogen [20]. In a one year study, girls over the
age of 10 years with TS randomized to OCEE or TBE
had no observed differences in serum levels of HDL,
LDL or triglycerides [21]. These results are specifically
important in girls with TS, who have increased incidence
of hypertension (40% of population), an atherogenic lipid
profile, and a higher risk of cardiovascular disease as
adults (3 fold increase in mortality) [22-24].
In our study, serum estradiol concentrations rose
over 18 months of estrogen therapy with all three
forms of estrogen, consistent with the physiologic rise
in estradiol through puberty. However, subjects treatedwith transdermal estrogen had significantly higher es-
tradiol levels at the maximum estrogen dose. This result
matches the more effective feminization demonstrated
in girls treated with TBE compared to OCEE at similar dose
equivalencies [21]. Our study also shows trends toward
higher estrone and estrone sulfate levels during treatment
with oral versus transdermal estrogen, but reaching statis-
tical significance only at 12 months. The inconsistent statis-
tical significance is likely due to the effect of small sample
size as well as large variability in serum concentrations of
estrone sulfate. This phenomenon is likely representative of
the first-pass metabolism of oral estrogen through the liver
and conversion of estradiol to estrone. These results are
similar to other studies comparing the use of OBE and TBE
in girls with TS [1,25]. Systemic absorption of estradiol via
the transdermal route avoids initial metabolism through
Figure 3 Proportion of subjects in each treatment group to reach Tanner breast stage 3 assessed at each study interval.
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sociated with OCEE. However, our study did not con-
clusively show differential effects on inflammatory
markers or lipid or liver profiles. These differences in
biochemical markers seen between the use of oral and
transdermal estrogen in older women have not to date
translated to adolescent girls.
We observed more effective feminization in girls treated
with TBE and OBE compared to OCEE. This could be ex-
plained by more consistent levels of estrogen, mimickingTable 4 Selected parameters (Mean ± SE) before and 6
months after introduction of progesterone (n = 8)
Before progesterone On progesterone
Height (cm) 152 ± 2.2 153.3 ± 2.2a
Weight (kg) 50.3 ± 7.7 53.1 ± 7.2a
Estradiol (pg/mL) 26 ± 10.4 11 ± 3.7
Estrone Sulfate (ng/dL) 204 ± 75 217 ± 115
HS-CRP (mg/L) 1.82 ± 1.42 3.83 ± 1.94
Fibrinogen Activity (mg/dL) 267 ± 32.2 310 ± 30.5
Antithrombin Activity (%) 109 ± 3.1 117 ± 7.2
Glucose (mg/dL) 81 ± 2.2 80 ± 1.6
ALT (U/L) 21 ± 5.5 26 ± 7.8
Triglycerides (mg/dL) 122 ± 23.6 111 ± 20
LDL (mg/dL) 84 ± 6.8 84 ± 5.7
IGF-1 (ng/mL) 416 ± 55 314 ± 56
Menses 50 %
ap < 0.05, difference in mean values between groups.spontaneous puberty [26]. The lack of menarche in over
half of the subjects with intact uterus was likely due to
insufficient estrogen exposure prior to the introduction of
progesterone as demonstrated by the pre-pubertal size of
the uterus on ultrasound in some of the girls. While rates
of feminization were similar between girls treated with
TBE and OBE, more girls treated with TBE achieved
menarche. It is difficult to know if insufficient estrogen-
ization of the uterus was due to the mode of estrogen
delivery, the dose of estrogen, or due to patient adher-
ence to the therapy. Torres-Santiago et al. demonstrated
that doses in excess of our maximal estrogen doses
(TBE 0.75-1 mg and OBE 2 mg) are required to maintain
estradiol levels comparable to normally menstruating ado-
lescent females, suggesting that dosage may have played a
role in our results [1].
There are several limitations of our study including the
small number of subjects, high variability of biochemical
markers among patients, and the effects of underlying
medical condition on inflammatory markers and liver
and lipid metabolism. Due to our small sample size we
were unable to separate subjects with TS or treated with
growth hormone in our analysis. There was a trend to-
wards higher IGF-1 levels with increasing doses of estrogen;
however without separation of the subjects on rGH in the
analysis the isolated effects of estrogen on IGF-1 would be
difficult to discern. The large variability in estradiol and
estrone sulfate levels could reflect the relationship
between sample collection and administration of the
medication, especially for estradiol levels in subjects on
oral preparations (OCEE and OBE). Also, one cannot
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when comparing the biochemical profiles of oral versus
transdermal estrogen after 18 months of hormone therapy.
The lack of differential effects of progesterone therapy is
contrary to prior studies [16,17], but may be due to our
small sample size, the potential variable of the timing of
the sample collection in relation to the menstrual cycle, or
the use of micronized progesterone rather than the more
typical medroxyprogesterone.
Conclusions
In summary, we observed higher estradiol levels and
more effective feminization in girls treated with trans-
dermal estrogen but no differences in other biochemical
markers. Given widespread concerns about the use of
oral conjugated estrogens, but no convincing evidence of
differential biochemical profiles between oral and trans-
dermal estradiol to date in adolescents, either oral or
transdermal 17β estradiol could provide safe and effective
alternatives to OCEE to induce puberty in girls. Larger
prospective randomized trials that can account for the
various underlying etiologies of ovarian failure are still re-
quired to determine the ideal regimen of estrogen delivery
to adolescent females, but sufficient concerns surrounding
the use of OCEE suggest the preferential use of oral or
transdermal 17β estradiol.
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